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Background: Overexpression of Decoy Receptor 3 (DcR3), a soluble member of the tumor necrosis factor receptor
superfamily, is a common event in several types of cancer. In renal cell carcinoma (RCC), DcR3 overexpression is
associated with lymph node and distant metastasis as well as a poor prognosis. However, the functional role and
regulation of DcR3 expression in RCC is so far unknown.
Methods: Modulation of DcR3 expression by siRNA and ectopic gene expression, respectively, was performed in
ACHN and 769-P RCC cell lines. Functional effects of a modulated DcR3 expression were analyzed with regard to
migration, invasion, adhesion, clonogenicity, and proliferation. Furthermore, quantitative RT-PCR and immunoblot
analyses were performed to evaluate the expression of downstream mediators of DcR3. In further experiments,
luciferase assays, quantitative RT-PCR and immunoblot analyses were applied to study the regulation of DcR3
expression in RCC. Additionally, an ex vivo tissue slice culture technique combined with immunohistochemistry was
used to study the regulation of DcR3 expression in human RCC specimens.
Results: Here, we show that DcR3 promotes adhesion, migration and invasiveness of RCC cells. The DcR3-dependent
increase in cellular invasiveness is accompanied with an up-regulation of integrin alpha 4, matrixmetalloproteinase 7
and urokinase plasminogen activator (uPA). Further, we identified a signaling pathway regulating DcR3 expression in
RCC. Using in vitro experiments as well as an ex vivo RCC tissue slice culture model, we demonstrate that expression of
DcR3 is regulated in a PI3K/AKT-dependent manner involving the transcription factor nuclear factor of activated T-cells
(NFAT).
Conclusions: Taken together, our results identify DcR3 as a key driver of tumor cell dissemination and suggest DcR3 as
a promising target for rational therapy of RCC.
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Renal cancer accounts for 2.6 percent of all malignant
diseases, with RCC (renal cell carcinoma) as the main
type of tumor. Around 25% of patients diagnosed with
RCC present with advanced disease, including metastasis
of the primary tumor. With the onset of metastasis the
median survival times for patients range between 10.9 and* Correspondence: Wilfried.Roth@med.uni-heidelberg.de
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reproduction in any medium, provided the or29.9 months, depending on the drugs used [1,2]. One
reason for the dismal prognosis is the poor response rate
to many therapeutic approaches, such as chemotherapy or
radiotherapy [3]. The development of (clear cell) renal cell
carcinoma is closely linked to the loss of the VHL (von
Hippel-Lindau) tumor-suppressor gene, encoding for a
protein promoting the degradation of the transcriptional
activators HIF1α (hypoxia-inducible factor) and HIF2α.
With the loss of VHL, several hypoxia-inducible genes
such as VEGF (vascular endothelial growth factor), TGF-α
(transforming growth factor α), GLUT-1 (glucose trans-
porter type 1) and carboanhydase 9 are overexpressed andtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AKT-mTOR (mammalian target of rapamycin) pathway
and deregulation of receptor tyrosine kinases contribute
to the progression of RCC. These molecular aberrations
are targeted by novel therapy strategies such as inhibitors
of mTOR or tyrosine kinases [7]. Further, defects in the
induction of apoptotic cell death, immune evasion mecha-
nisms and a high metastatic potential are determinants of
RCC. In these processes, the members of the TNF (tumor
necrosis factor) superfamily play an important role. DcR3
(Decoy Receptor 3) is a soluble member of the TNFR
(tumor necrosis factor receptor) superfamily [8]. DcR3 is
capable to bind and neutralize CD95 ligand (CD95L, FasL,
APO1L), TL1A (TNF-like molecule 1A) and LIGHT. By
binding to these ligands DcR3 can inhibit apoptosis,
induce angiogenesis and modulate immune cell functions
[9-13]. Apart from its decoy function, DcR3 has been
shown to induce macrophage differentiation as well as
osteoclast formation [14,15]. Clinical data link DcR3
overexpression to different types of cancer, such as
pancreatic, lung, hepatocellular and colorectal cancer
[8,16-18]. In the tumor entities examined so far, over-
expression of DcR3 correlates with higher grading,
staging and metastasis [18-21]. In our previous work,
we showed that DcR3 expression in RCC is associated
with high grade and high stage tumors [19]. Moreover,
DcR3 expression correlated with lymph node metastasis
and distant metastasis. In addition, DcR3 negatively corre-
lated with disease specific survival and progression free
survival and qualified as an independent prognostic factor.
In this study, we sought to explore the functional role
of DcR3 in RCC. We demonstrate that DcR3 promotes
adhesion, migration and invasiveness of RCC cells which
is accompanied by an up-regulation of integrin alpha
4, matrixmetalloproteinase 7 and urokinase plasminogen
activator (uPA). Further, we show that expression of DcR3
is regulated in a PI3K/AKT-dependent manner. Taken
together, our results identify DcR3 as a key driver of
tumor cell dissemination and suggest DcR3 as a promising
target for rational therapy of RCC.
Results
DcR3 promotes migration of RCC cells
As our previous work demonstrates a clinical significance
of DcR3 overexpression in RCC [19], we were interested
in functionally characterizing DcR3 in RCC. To this end,
we started to analyze several RCC cell lines for endogenous
expression of DcR3 on mRNA and protein level by
quantitative RT-PCR and immunoblot analysis. Human
embryonic kidney derived 293-T cells were used as a con-
trol kidney cell line. Six out of eight RCC cell lines showed
a moderate to high expression of DcR3 whereas 293T cells
lacked DcR3 expression (Figure 1A; Additional file 1:
Figure S1A). As DcR3 is a soluble protein, we additionallyinvestigated its secretion by DcR3 expressing tumor cells.
We detected DcR3 in the supernatant of all DcR3 express-
ing cell lines tested (Figure 1B).
Using these RCC cell lines, we aimed at characterizing
the involvement of DcR3 in the regulation of cellular
migration, invasion and adhesion. To analyze the effect
of DcR3 expression on migratory ability we either down-
regulated DcR3 using two different siRNAs (Figure 1C)
or established transfectants stably overexpressing DcR3
(Figure 1D) and subjected the cells to scratch motility as-
says. By cytotoxicity analysis we confirmed that modulation
of DcR3 expression was functional, as DcR3 overexpression
protected cells from CD95L-induced apoptosis, while DcR3
knockdown sensitized cells to CD95L-induced apoptosis
(Additional file 1: Figure S1B,C). The siRNA-mediated
suppression of DcR3 expression significantly reduced
the migratory ability of both cell lines tested (Figure 1E;
Additional file 1: Figure S1D), whereas stable over-
expression resulted in a strong increase of migration
(Figure 1F; Additional file 1: Figure S1E). Consistently,
addition of DcR3-containing supernatant rescued the
migratory ability of cells with diminished DcR3 expression
levels (Figure 1G). To ensure, that our findings are not
due to alterations in proliferative capacity, we determined
the proliferation rate dependent on DcR3 expression.
Downregulation as well as overexpression did not change
the proliferative activity nor did it affect clonogenicity
(Additional file 2: Figure S2A-D).
DcR3 increases invasiveness in RCC cells
Next, we tested whether an alteration in DcR3 expression
affects the ability of RCC cells to invade the extracellular
matrix. While knockdown of DcR3 substantially reduced
the invasive capacity (Figure 2A), overexpression strongly
enhanced the invasiveness in both cell lines tested
(Figure 2B). In addition to the matrigel-coated invasion
assay, we studied the invasiveness of RCC cells in a more
complex extracellular matrix assay. Cells were grown to
form spheroids, which were then implanted into a collagen
type I gel-matrix. In line with the matrigel invasion results,
overexpression of DcR3 significantly enhanced the invasive
phenotype of both cell lines tested (Figure 2C).
Regulation of cellular adhesion to fibronectin by DcR3
As both migration and invasion are dynamic processes
involving attachment and detachment to extracellular
matrix proteins, we wondered whether the alteration of
DcR3 expression might have effects on cellular adherence.
To this end, we analyzed the ability of cells with modulated
DcR3 expression to attach to cover glasses coated with
fibronectin, which is present in RCC [22] and metastatic
niches [23]. Interestingly, DcR3 knockdown decreased
the ability to adhere to fibronectin (Figure 3A), while
overexpression augmented adherence (Figure 3B). Based
Figure 1 DcR3 promotes cellular migration in RCC. (A) Immunoblot analysis of whole-cell lysates showing DcR3 protein levels in different
human RCC cell lines and human embryonic kidney 293-T cells. (B) Immunoblot analysis of precipitated protein from supernatant showing DcR3
protein secretion in different human RCC cell lines and human embryonic kidney 293-T cells. Ponceau staining is used to demonstrate equal
protein loading. (C,D) Immunoblot analysis of whole-cell lysates (left) and precipitated protein from supernatant (right) of ACHN and 769-P cells
transfected with two different DcR3-specific siRNAs or a non-specific siRNA (scram) (C) or stably overexpressing DcR3 or an empty control vector
(neo) (D). (E) Scratch motility assay of ACHN and 769-P cells transfected with two different DcR3-specific siRNAs or a non-specific siRNA (scram).
Bars indicate the percentage of cell migration in relation to cells transfected with a non-specific siRNA after 24 h (mean ± SEM; n=3; *p<0.05,
**p<0.01; T-test). Representative images are shown in Additional file 1: Figure S1D. (F) Scratch motility assay of ACHN and 769-P cells stably
overexpressing DcR3 or an empty control vector (neo). Migration was measured over a time course of 12 h (ACHN) or 24 h (769-P). Bars indicate
the percentage of cell migration in relation to cells stably transfected with an empty control vector (mean ± SEM; n=3; *p<0.05, **p<0.01, T-test).
Representative images are shown in Additional file 1: Figure S1E. (G) Scratch motility assay of ACHN and 769-P cells transfected with two different
DcR3-specific siRNAs or a non-specific siRNA (scram) and incubated with either DcR3-containing or control supernatant (SN) of stable
transfectants. Migration was measured over a time course of 24 h. Bars indicate the percentage of cell migration in relation to cells transfected
with a non–specific siRNA and treated with control supernatant (mean ± SEM; n=3; *p<0.05, **p<0.01; T-test).
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the expression of genes commonly associated with migra-
tion, invasion or adhesion. Interestingly we found a DcR3
dependent alteration of expression levels for ITGA4
(integrin alpha 4), MMP7 (matrixmetalloproteinase 7)
and uPA (urokinase plasminogen activator) whereas ex-
pression levels of ITGB1 (integrin beta 1), MMP2 and
MMP9 were unchanged (Figure 3C-F).PI3K/AKT signaling regulates DcR3 expression in RCC
Both the expression data derived from human RCC
samples [19] as well as the functional results obtained
in the cell culture model indicate a key role of DcR3 in
the process of invasion and metastasis. However, the
mechanisms responsible for overexpression of DcR3 in
RCC are not known. Since the PI3K/AKT pathway is
deregulated in RCC [24], we investigated its involvement
Figure 2 DcR3 promotes invasiveness in RCC cells. (A,B) Boyden chamber assay of ACHN and 769-P cells transfected with two different
DcR3-specific siRNAs or a non-specific siRNA (scram) (A) or stably overexpressing DcR3 or an empty vector control (neo) (B). Bars indicate the
percentage of cellular invasion in correlation to control cells. Invaded cells were counted in five representative fields (mean ± SEM; n=3, **p<0.01,
***p<0.001; T-test). Representative images are shown (magnification: 200×). (C) Spheroid assay of ACHN and 769-P cells stably overexpressing
DcR3 or an empty control vector (neo). Bars indicate the percentage of cell invasion in relation to cells stably transfected with an empty control
vector (mean ± SEM; n=3; *p<0.05, T-test). Representative images are shown (magnification: 40×).
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cell lines with both the PI3K-inhibitor LY294002 and the
AKT-inhibitor IV (CAS-number: 681281-88-9) resulted
in a strongly reduced DcR3 expression on both protein
and mRNA level, indicating a regulation of DcR3 on
the transcriptional level (Figure 4A). Correspondingly,overexpression of the constitutively active form of AKT
led to an increased DcR3 expression (Figure 4B). The
successful modulation of the PI3K/AKT pathway was
further confirmed by analyzing the phosphorylation of
AKT, its direct downstream target GSK-3β, the mTOR
target P70S6K (Figure 4A,B) and by measuring the
Figure 3 (See legend on next page.)
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Figure 3 DcR3 modulates cell adhesion to ECM component fibronectin. (A,B) Adhesion assay of ACHN and 769-P cells transfected with two
different DcR3-specific siRNAs or a non-specific siRNA (scram) (A) or stably overexpressing DcR3 or an empty vector control (neo) (B). Bars
indicate the percentage of cell adhesion compared to control cells. Adherent cells were counted in five representative fields (mean ± SEM; n=3,
*p<0.05, **p<0.01; ***p<0.001; T-test). Representative images are shown (magnification: 100×). (C,D) Quantitative real-time-PCR assaying relative
expression levels of DcR3 and invasion-relevant genes in ACHN and 769-P cells transfected with two different DcR3-specific siRNAs or a non-
specific siRNA (scram) (C) or stably overexpressing DcR3 or an empty vector control (neo) (D). Expression data were normalized to internal 18S
rRNA expression. Bars indicate fold changes of RNA level in relation to control cells (mean ± SEM; n=3; *p<0.05; **p<0.01; T-test). (E) Immunoblot
analysis of whole-cell lysates showing uPA protein level in ACHN and 769-P cells transfected with two different DcR3-specific siRNAs, a non-
specific siRNA (scram) or stably overexpressing DcR3 or empty vector control (neo). (F) Immunoblot analysis of whole-cell lysates showing ITGA4
protein level in ACHN and 769-P cells stably overexpressing DcR3 or an empty vector control (neo).
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file 3: Figure S3A,3B). We further evaluated the role of
GSK-3β and mTOR in the PI3K/AKT-dependent DcR3
regulation. Knockdown of GSK-3β, whose activity is nega-
tively regulated by AKT, resulted in a moderate increase
of DcR3 expression (Figure 4C). In contrast, the inhibition
of mTOR using Everolimus had no impact on DcR3
expression (Figure 4D).
NFATc1 mediates PI3K/AKT-dependent DcR3 expression
GSK-3β and the family of FOXO transcription factors
are both known to negatively regulate the transcription
factor NFAT (nuclear factor of activated T-cells) [25].
Therefore, we investigated its role in the transcriptional
regulation of DcR3. We treated the cells with Cyclosporine
A or FK-506 (Tacrolimus) which are both immunosuppres-
sants that inactivate calcineurin, the major activator of
NFAT. Inhibition of calcineurin dramatically decreased
the expression of DcR3 (Figure 5A), indicating a functional
relevance of NFAT in DcR3 regulation. Accordingly, NFAT
overexpression resulted in an increase in DcR3 expression
level (Figure 5B). To demonstrate that modulation of the
PI3K/AKT pathway affects NFAT expression, we performed
nuclear and cytoplasmic fractionation and detected a
shift of NFAT localization to the cytoplasm upon PI3K
inhibition. A similar shift was detectable after Cyclosporine
A treatment which served as a positive control. In con-
trast, treatment with Everolimus had no impact on NFAT
localization, confirming an mTOR independent regulation
(Figure 5C). In addition, the activity of NFAT was enhanced
upon overexpression of a constitutively active form of AKT
(Figure 5D).
PI3K/AKT signaling regulates DcR3 expression in ex vivo
cultured RCC tissue
To confirm the importance of PI3K signaling for DcR3
expression in human RCC, we incubated freshly resected
human RCC tissue slices with the PI3K-inhibitor LY294002.
The inhibition of PI3K signaling significantly diminished
DcR3 expression in all six examined cases, as assessed
by immunohistochemistry (Figure 6A). These results were
confirmed by immunoblot analyses of lysates generatedin parallel (Additional file 3: Figure S3C). Furthermore,
treatment of RCC tissue slices with LY294002 resulted
in a reduced proliferation in four out of five cases as
assessed by Ki-67 staining. At the same time, apoptosis
(assessed by immunohistochemical detection of cleaved
caspase 3) was not induced to a significant extent by
LY294002 (data not shown).To further examine a possible
association of AKT activation levels and DcR3 expression,
we subjected nine pairs of freshly obtained human RCC
tissue and adjacent normal renal tissue to immunoblot
analysis. Although a clear quantitative association of AKT
phosphorylation and DcR3 expression levels was not
evident, the majority of DcR3 positive tumor samples
also showed elevated levels of active AKT compared to
their corresponding normal tissue samples (Figure 6B).
Discussion
In our previous work we found a significant association of
DcR3 expression levels and both lymph node and distant
metastasis in a large collection of 560 human RCC
samples [19]. Further, DcR3 expression was identified
as a robust independent negative prognostic marker in
patients with RCCs. In the present study we sought to
elucidate the functional relevance of DcR3 for cellular
migration, invasiveness and metastasis. Moreover, we
investigated the mechanisms of how DcR3 expression
is regulated in RCC.
Our results indicate that DcR3 is an important driver
of adhesion, migration and invasiveness in RCC. Since
these functional characteristics are hallmarks of the
metastatic process the findings are in accordance with
the clinical correlation of DcR3 expression and metastasis.
Similar results obtained by studies of other types of cancer,
such as breast and nasopharyngeal cancer, confirm the
promoting effect on metastasis and invasiveness of DcR3
[26,27]. In addition to our functional observations, we
found that DcR3 regulates the expression of proteins
involved in migration and invasiveness. Modulation of
DcR3 expression resulted specifically in transcriptional
regulation of MMP-7, uPA and ITGA4, whereas the ex-
pression of other members of the matrixmetalloproteinase
and integrin families was not altered. In a recent study of
Figure 4 DcR3 expression in RCC is PI3K/AKT-dependent. (A-D) Immunoblot analysis of whole-cell lysates and quantitative real-time-PCR
assaying relative DcR3 mRNA expression of ACHN and 769-P cells 24 h after treatment with LY294002 (50 μM) or AKT-inhibitor IV (10 μM) (A);
48 h post transfection with constitutively active AKT (myrAKT) or an empty vector control (neo) (B); 48 h post transfection with GSK-3β-specific
siRNAs or a non-specific siRNA (scram) (C); 24 h after treatment with Everolimus (1 μM) (D). Expression data were normalized to internal 18S rRNA
expression (mean ± SEM; n=3; *p<0.05, **p<0.01, ***p<0.001; T-test).
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Figure 5 NFATc1 regulates DcR3 expression at a transcriptional level. (A,B) Immunoblot analysis of whole-cell lysates and quantitative
real-time-PCR assaying relative DcR3 mRNA expression of ACHN and 769-P cells 24 h after treatment with cyclosporin A (CsA, 25 μM) or
Tacrolimus (FK-506, 50 μM) (A); 48 h post transfection with NFATc1 or an empty vector control (neo) (B). Expression data were normalized
to internal 18S rRNA expression (mean ± SEM; n=3; *p<0.05, **p<0.01, ***p<0.001; T-test). (C) Immunoblot analysis of cytoplasmic and
nuclear fractions of ACHN and 769-P cells after treatment with LY294002 (50 μM), Everolimus (1 μM), or Cyclosporine A (25 μM). (D) Relative
NFATc1–luciferase reporter activity of ACHN and 769-P cells 24 h post transfection with myrAkt or an empty vector control (neo)
(mean ± SEM; n=3; *p<0.05, **p<0.01; T-test).
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a whole network of proteins. ITGA4, uPA and members of
the MMP-family were positively regulated by DcR3 [28].
Additionally, DcR3 was shown to upregulate ITGA4 in
macrophages [29]. These data provide additional evidence
that DcR3 is involved in the induction of metastasis–asso-
ciated genes. Interestingly, MMP7, uPA and ITGA4 have
been shown to correlate with metastatic potential in RCC.
ITGA4 is exclusively expressed in RCC in comparison to
normal kidney tissue [30] and is associated with metastaticspread of RCC and other solid tumor entities by interacting
with its ligands VCAM-1 (vascular cell adhesion protein 1)
and fibronectin [31,32]. VCAM-1 and ICAM-1 (intercel-
lular adhesion molecule 1) are other proteins that were
shown to be upregulated upon DcR3 exposure on endo-
thelial cells [33]. Since the interaction of ITGA4 with
VCAM-1 is essential for the leukocyte adhesion cascade
involving rolling, adhesion and transmigration through
endothelial cells, DcR3 might enable cancer cells to mim-
icry this process in order to form distant metastasis. Such
Figure 6 DcR3 expression in human RCC specimens is PI3K/AKT-dependent. (A) Immunohistochemical analysis of DcR3 expression in
ex vivo tissue samples 48 h after treatment with LY294002 (100 μM). Representative images are shown (magnification: 100×). (B) Immunoblot
analysis of DcR3 and phospho-AKT protein levels in nine different pairs of RCC and respective normal renal tissue.
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(tumor necrosis factor α) stimulation in oral squamous
cell carcinoma [34]. In addition, MMP-7 and uPA expres-
sion correlate with metastasis and poor survival rates in
RCC [35,36]. The precise mechanism of DcR3 signaling
remains unknown but could involve binding to the
heparan sulfate proteoglycans syndecan-2 and CD44v3,
both exerting downstream effects on Src (Rous sarcoma
oncogene cellular homolog), Ras and consequently STAT3
(signal transducer and activator of transcription 3) signaling
[37-40]. In our experiments we could confirm a role of
STAT3 in DcR3 signaling (data not shown), whereas Src
amongst other pathways such as PKC (protein kinase
C)-, PI3K- and FAK (fokal adhesion kinase)-dependent
signaling is influenced by DcR3 in immune cell response
[41]. Since both MMP-7 and ITGA4 are transcriptionallyregulated by STAT3, Src/STAT3 signaling might explain
the transcriptional regulation of MMP-7 and ITGA4 in
the context of DcR3 [42,43].
The mechanisms of regulation of DcR3 expression in
RCC have not yet been investigated. Our study demon-
strates that DcR3 expression is regulated by a PI3K/
AKT-dependent mechanism. In human pancreatic adeno-
carcinoma, DcR3 expression has been linked to PI3K/AKT
signaling in cooperation with NFκB (nuclear factor κB),
however, without further investigation of possible down-
stream mediators [44]. Another study linked Epstein-Barr
virus transcription activator Rta to PI3K/AKT and NFκB
signaling and increased DcR3 expression [45]. As AKT
influences a whole network of proteins and interacts
with different other pathways we evaluated the role of
two major AKT downstream targets. Thereby we could
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In contrast, GSK-3β turned out to be involved in the
regulation of DcR3 expression. GSK-3β is capable of
inactivating the transcription factor NFAT by phos-
phorylation, leading to a translocation of NFAT into
the cytoplasm, which renders it unable to induce transcrip-
tion of its downstream targets [25]. FOXO can increase
the expression of atrogin-1, which is able to ubiquitinate
calcineurin, consequently leading to a decrease in NFAT
activation [46]. Via further experiments, we could describe
NFAT as the main driver of DcR3 expression. Recently,
possible cross-talks between NFAT and NFκB were de-
scribed in bronchial epithelial cells [47] and in cardio-
myocytes [48]. In line with these observations, we
observed a decreased expression of DcR3 upon p65/RelA
knockdown (data not shown). Since the PI3K/AKT path-
way is able to positively regulate NFκB signaling [49],
the PI3K/AKT/NFAT-mediated regulation of DcR3 might
additionally be enhanced by the PI3K/AKT/NFκB axis. As
the TNF superfamily shows structural similarities, one
might assume similar mechanisms regarding regulation
of expression. Interestingly, the soluble TNF superfamily
members TRAIL (TNF-related apoptosis inducing ligand),
CD95L, RANK-L (receptor activator of NFκB ligand) and
TNF-α are upregulated by NFAT and SP-1 [50-54]. In
contrast, the role of NFAT in the regulation of death
receptors has not been examined in detail so far. SP-1 was
reported to upregulate the expression of TRAIL-R2 (DR5;
death receptor 5), while analysis of the other TNFR mem-
bers is still missing [55]. In line with these observations we
could also detect a decrease of DcR3 expression upon SP-1
inhibition or SP-1 knockdown (data not shown). Thus,
similar mechanisms regulate the expression of different
members of the TNF and TNFR superfamilies.
As DcR3 emerges as a multimodal molecule capable of
promoting tumor progression by neutralizing apoptosis-
inducing ligands, modulating the immune system in a
pro-tumorigenic way as well as promoting metastasis
of cancer cells, DcR3 might be a promising therapeutic
target. The fact, that DcR3 is a secreted protein implies
that DcR3 is capable of acting on its different target cells
in a paracrine as well as a systemic manner, rendering
it a powerful tool of the tumor to modulate the host
system to form metastasis. On the other side, DcR3 is
easily detectable in the blood serum of patients, opening
up the possibility to use DcR3 as a biomarker for risk
of metastasis and aggressive disease. Moreover, DcR3
expression could qualify as an indicator for the response
and efficacy of a PI3K/AKT-targeting therapy. If the correl-
ation between DcR3 expression and PI3K/AKT signaling
activities proves to be stable in patients, the evaluation of
DcR3 levels in urine or blood samples of patients could
allow a selection of patients for treatment with PI3K/
AKT-targeting therapeutics such as NVP-BEZ235 orSF1126 which are already in clinical trials for RCC and
other solid tumor entities (NCT01453595; NCT00907205).
SF1126 is a RGDS-conjugated LY294002 prodrug which
is converted to the active compound LY294002 under
physiologic conditions [56]. SF1126 is characterized by
an increased solubility, by a prolonged half-life and by
an improved delivery to the tumor [56]. It was recently
evaluated in a phase I clinical trial in advanced solid tumors
and B cell malignancies and has been proven to be well
tolerated [57]. However, similarly to Ly294002 [58], SF1126
is likely to target signaling pathways other than PI3K/AKT,
such as GSK3, mTOR and PI4K. So far the efficacy of a
PI3K/AKT-targeting therapy in patients with RCC is not
clear. DcR3 could serve as an easily measurable indicator
for response, as DcR3 protein level should decrease upon
PI3K/AKT inhibition. PI3K/AKT activation is a common
event in cancer progression, either by loss of PTEN (phos-
phatase and tensin homolog) or activation of receptor
tyrosine kinases by stimuli such as TGF-α or VEGF [59]
the latter being highly upregulated in clear cell renal
cancer. Consequently, PI3K/AKT-signaling is highly active
in RCC and correlates with tumor burden and metastasis
[60]. Thus, our findings suggest a new role of DcR3 in
the context of rationally treating RCC patients. Our
study warrants the further investigation of DcR3 in clinical
settings.Conclusions
This is the first study on the regulation and function of
DcR3 in RCC. Our experiments identify DcR3 as a
driver of adhesion, migration and invasiveness in RCC
cells. These results confirm previous data demonstrating
that DcR3 expression can be used as a biomarker for
poor prognosis and risk of metastasis. Furthermore, we
identified that DcR3 is regulated via a signaling axis
involving PI3K/AKT and NFATc1. This newly discovered
signaling pathway could be therapeutically exploited,
since the subgroup of patients with DcR3 positive RCC
might benefit from the inhibition of the drugable targets
PI3K/AKT and NFATc1.Methods
Reagents
Everolimus (#07741) was obtained from Sigma Aldrich
(St. Gallen, Switzerland), LY294002 (#70920) was pur-
chased from Cayman Chemicals Company (Ann Arbor,
MI, USA) and AKT-inhibitor IV (#124011) was purchased
from Calbiochem (Darmstadt, Germany). Cyclosporine A
(#BML-A195) and CD95L (#ALX-522-001) were bought
from Enzo life science (Loerrach, Germany). FK-506/
Tacrolimus (#10007965) was purchased from Biozol
(Eching, Germany).
Weissinger et al. Molecular Cancer 2013, 12:120 Page 11 of 15
http://www.molecular-cancer.com/content/12/1/120Cell culture
Human RCC cell lines 786-O, 769-P, ACHN, HTB-45
and 293-T were purchased from ATCC (Rockville, MD,
USA). At ATCC the cell lines were authenticated by short
tandem repeat profiling. KTCTL-2, KTCTL-26, KTCTL-30
and KTCTL-84 were obtained from the tumor cell bank
of the German cancer research center (DKFZ; Heidelberg,
Germany). All cell lines were maintained in RPMI1640
medium (Life Technologies, Gaithersburg, MD, USA)
supplemented with 10% fetal calf serum, 1 mM glutamine,
25 mM glucose and 1% penicillin/streptomycin (Life
Technologies) and cultured at 37°C in a 5% CO2 atmos-
phere. For experiments, cells were cultured for no more
than 10 passages. In addition, cell lines were regularly
tested for contamination by multiplex PCR performed in
the Genomics and Proteomics Core Facility [61] (DKFZ,
Heidelberg, Germany). Trypan blue exclusion assay was
used for cell viability evaluation.
Transfections
Knockdown of endogenous protein was achieved by
transiently transfecting cell lines with short interfering
RNA (siRNA) oligonucleotides at a concentration of 25 nM
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
All siRNAs were obtained from Dharmacon (Lafayette,
CO, USA): DcR3_si1 (#D-008102-02), DcR3_si2 (#D-
008102-04), GSK-3β_si (#J-00310-12). A non-specific
siRNA served as a control (#D-001810-10). For transient or
stable overexpression, cells were transfected with pcDNA3
(Invitrogen), pcDNA3-DcR3 (generated as outlined below),
myrAkt δ4 (Addgene Plasmid 10841) [62] and NFATc1
(Addgene Plasmid 11788) [63] both obtained from
Addgene (Cambridge, MA, USA), using Lipofectamine
2000 (Invitrogen). The pcDNA3-DcR3 plasmid was
generated by PCR from the clone pENTR223-TNFRSF6B,
provided by the ORFeome Collaboration via the Genomics
and Proteomics Core Facility (DKFZ, Heidelberg, Germany)
using the following forward (F) and reverse (R) primers
containing BamHI and EcoRI restrictions sites: 5′-GA
TCATGTAGAGGATCCACCATGAGGGCGCTGGAG
GGG-3′ (F) and 5′-ATACTGCTACGAATTCTCAGTGC
ACAGGGAGGAAGC-3′ (R). The PCR products were
digested with BamHI and EcoRI and cloned into the
BamHI and EcoRI sites of pcDNA3 (Invitrogen). For
the generation of stable transfectants, complete medium
containing Geneticin® (G418, Invitrogen) at a concentra-
tion of 1.5 mg/mL was used to select stably transfected
cells.
Preparation and culture of tissue slices and
immunohistochemistry
The usage of tumor tissue for research purposes was
approved by the local ethics committee of the University
Hospital of Heidelberg, Germany. All data were analyzedanonymously. Written informed consent from the donors
or the next of kin was obtained for use of these samples in
research. Fresh human renal cell carcinoma tissue samples
were obtained from the Tissue Bank of the Center for
National Tumor Diseases (NCT, Heidelberg, Germany)
directly after surgery and maintained in DMEM medium
on ice. Tissue samples were cut into 300 μm thick slices
by a Leica VT1200 S vibrating blade microtome (Leica,
Wetzlar, Germany). Slices were then placed on porous
filter membrane inserts in six-well plates and cultured
in DMEM supplemented with penicillin (100 U/mL) and
streptomycin (100 mg/mL) (Sigma Aldrich) in a conven-
tional CO2 incubator. After 24 hours, slices were treated
with LY294002 for further 24 h. After treatment, tissue
slices were fixed in 10% neutral-buffered formalin and
embedded in paraffin. Four micrometer sections were
stained with H&E or subjected to immunohistochemistry.
Paraffin-embedded tissue sections were dewaxed and
rehydrated using xylene and a series of graded alco-
hols, followed by heat-induced antigen retrieval with a
target retrieval solution (S2301, DakoCytomation, Glostrup,
Denmark) in a pressure cooker for 15 min. For staining
an automated staining system (Techmate 500, Dako-
Cytomation) with avidin-biotin-complex peroxidase tech-
nique using aminoethylcarbazole for visualization and
hematoxylin for counterstaining was used. Sections were
incubated with primary antibody (anti-DcR3; BioLegend;
London, United Kingdom; #333202; 6.25 μg/mL) for
30 min at room temperature and processed according to
manufacturer’s protocol for the following kits: ChemMate
Detection Kit (K5003, DakoCytomation), ChemMate Buffer
Kit (K5006, DakoCytomation), Avidin/Biotin Blocking
Kit (SP-2001, Vector Laboratories, Burlingame, CA, USA).
For negative control of the staining procedure, primary
antibody was omitted with all other experimental condi-
tions kept constant.
Reporter gene assays
Cells were seeded into 12-well dishes and co-transfected
with Renilla luciferase pRL-SV40P (Promega, Madison,
WI, USA) and FHRE-Luc (Addgene Plasmid 1789) [64] or
pGL3-NFAT luciferase (Addgene Plasmid 17870) [65].
24 h after transfection cells were subjected to LY294002
or AKT-inhibitor IV treatment for further 24 h prior
to the preparation of cell lysates. Both Firefly and
Renilla luciferase activities were quantified using the
dual-luciferase-reporter assay system (Promega), according
to the manufacturer’s instructions.
Quantitative real-time PCR
Quantitative real-time PCR was performed as described
previously [66]. Following primer pairs were used:
DcR3: 5′-CCACTACACGCAGTTCTGGA-3′ (forward)











integrin alpha 4: 5′-GAGTGCAATGCAGACCTTGA-3′
(forward)
5′-GGCCTTCCAGTTGGATATGA-3′ (reverse)








Cells were rinsed with ice-cold PBS and lysed with lysis
buffer (120 mM NaCl, 50 mM Tris–HCl (pH 8.0),
5 mM EDTA, 0.5% Triton X-100) containing pheny-
lmethylsulfonyl-flouride (1 mM), proteinase inhibitors
(Roche, Mannheim, Germany, #1697498) and phosphatase
inhibitors (25 mM NaF, 200 μM NaVO3, 10 mM NaPPi).
After 15 min incubation on ice, lysates were centrifuged at
16 000 g for 20 min. For cytoplasmic and nuclear fractions
cells were harvested and processed with the Nuclear
Extraction Kit (Active Motif, Rixensart, Belgium) according
to manufacturer’s protocol. For protein isolation from
human tissue, frozen tissue samples kindly provided by the
Tissue Bank of the Center for National Tumor Diseases
(NCT, Heidelberg, Germany) were suspended in 100 μl
lysis buffer and shock frozen in liquid nitrogen. Thereafter
5 mm grinding balls were added. The tissue samples were
homogenized by the use of a Mixer Mill MM 200 (Retsch,
Haan, Germany) and centrifuged for 10 min at 16 000 g.
For the isolation of proteins from supernatant, cells were
incubated in serum free medium. After 24–48 h the
medium was harvested and centrifuged for 5 min at
1000 g. 200 μL of the supernatant were used for precipita-
tion [67]. A Ponceau S-stained protein band was used for
normalization. Total protein concentration was measured
by Bradford-Assay (Bio-Rad, Munich, Germany). 20–40 μg
protein was separated on 10–15% polyacrylamide gels
and blotted onto nitrocellulose (Bio-Rad) by standard
procedures. Membranes were washed, incubated with
primary antibody over night, washed again incubated
with secondary antibody (1:3000) (horseradish peroxidase-
conjugated, Bio-Rad) and visualized by an enhanced
chemiluminescence detection system (GE Healthcare,Munich, Germany). Following primary antibodies were
used: anti-DcR3 (BioLegend, #333202), anti-β-actin (Merck
Millipore, Darmstadt, Germany, #mab1501), anti-AKT
(Cell Signaling, Danvers, MA, USA, #9272), anti-phospho-
AKT (Cell Signaling, #4058), anti-P70S6K (Cell Signal-
ing, #9202), anti-phospho-P70S6K (Cell Signaling, #9206),
anti-GSK-3β (Cell Signaling, #9315), anti-phospho-GSK-
3β (Cell Signaling, #9336), anti-PARP (BD Pharmingen,
San Diego, CA, USA, #556362), anti-Caspase 3 (Imgenex,
San Diego, CA, USA, #IMG-144A), anti-NFATc1 (Abcam,
Cambridge, MA, USA, #ab25916), and anti-ITGA4
(GeneTex, Irvine, CA, USA, #GTX61691).
Scratch motility assay
Cells (5 × 105) were seeded into 12–well culture dishes.
24 h thereafter, a 100 μm scratch was placed within the
confluent monolayer with a pipette tip. Cells were then
placed into the incubation chamber of an Olympus IX81
microscope and cultivated at 37°C, 40% humidity and
5% CO2. Throughout 24 h pictures were taken at intervals
of 1–2 h with an Olympus U-CMAD3 camera by CellR
software. Migratory activity was calculated with Image J
software, based on the cell-free areas.
Proliferation and clonogenicity assay
For the assessment of proliferation, 2.5 × 105 cells were
seeded into 6-cm culture dishes and counted after 24 h,
48 h and 72 h using the trypan blue exclusion assay. For
clonogenicity assays, 500 cells were seeded into 6–well
culture dishes and incubated for seven days prior to crystal
violet staining and colony counting.
Boyden chamber assay
The invasive capacity of cells was analyzed by the use of
Matrigel™ coated chambers (BD Bioscience, Sparks, MD,
USA) according to manufacturer’s protocol. Briefly, cells
were starved for 24 h with serum free medium. After
trypsinization, 105 cells, suspended in 0.5 mL serum free
medium, were seeded into the boyden chamber insert.
0.75 mL medium enriched with 20% FCS was added as a
chemoattractant into the well. Cells were allowed to
invade the Matrigel™ matrix for 24–48 h. Thereafter,
transmigrated cells were fixed and stained with crystal
violet.
Spheroid invasion assay
Cells (75 000–100 000) resuspended in 20 μL medium
were suspended on the lid of a 100-mm Petri dish to
form spheroids. 48 h later, spheroids were placed in cell
culture dishes, coated with 2% sterile agar (Merck)/PBS
(solidified) and filled with growth medium. 24 h later,
spheroids were embedded into collagen gels. Collagen
gels were made by mixing Vitrogen (97% collagen type I;
Nutacon BV, Leimuiden, the Netherlands) with 10-fold
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and sterile 0.1 M sodium hydroxide, resulting in a final
concentration of 2.4 mg/mL collagen. Collagen solution
was distributed into 24-well plates (0.5 mL/well) which
had previously been coated with 2% sterile agar (Merck)/
PBS (solidified). After solidification gels were overlaid with
growth medium. Cell invasion was monitored at intervals
of 24 h by photographing spheroids with an inverted
Olympus IMT2-RFA/340 phase contrast microscope.
Cytotoxicity assay
For acute cytotoxicity assays, 104 cells were plated in
96-well plates, adhered for 24 h, and exposed to CD95L
for 24 h. The percentage of surviving cells was assessed by
staining with crystal violet [68]. Briefly, the supernatant
was removed, and the cells were incubated in a 2% crystal
violet solution in 20% methanol for 10 min. The plates
were washed in running tap water and air-dried for 24 h.
Crystal violet was solubilized by the addition of a 0.1 M
sodium citrate buffer in 50% ethanol. The absorption was
measured at 550 nm using a microplate reader (Bio-Rad).
Statistical methods
For all data, significant differences were identified using the
unpaired 2-sided Student t test. Throughout, P values <
0.05 were considered significant and are indicated as
follows: *P < 0.05, **P < 0.01, ***P < 0.001.
Additional files
Additional file 1: Figure S1. DcR3 expression in RCC. (A) Quantitative
real-time-PCR assaying relative DcR3 mRNA expression levels. Expression
data were normalized to internal 18S rRNA expression. (B) Cytotoxicity
assay of ACHN and 769-P cells transfected with two different DcR3-
specific siRNAs or a non-specific siRNA (scram). Cells were treated with
CD95L (200 ng/μL) for 24 h prior to crystal violet staining (mean ± SEM;
n=3; **p<0.01; scram vs. DcR3-si1 and scram vs. DcR3-si2; T-test). (C)
Cytotoxicity assay of CD95L sensitive LN18 glioblastoma cells stably
overexpressing DcR3 or an empty vector control (neo). Cells were treated
with CD95L (200 ng/μL) for 24 h prior to crystal violet staining (mean ±
SEM; n=3; *p<0.05; T-test). Since ACHN and 769-P RCC cells are resistant to
CD95L induced cytotoxicity, CD95L sensitive LN18 glioblastoma cells were
chosen to analyze the protective effect of DcR3 overexpression. (D) Scratch
motility assay of ACHN and 769-P cells transfected with two different
DcR3-specific siRNAs or a non-specific siRNA (scram). Migration was
measured over a time course of 24 h. Representative images are shown
(magnification: 100×). (E) Scratch motility assay of ACHN and 769-P stably
overexpressing DcR3 or an empty control vector (neo). Migration was
measured over a time course of 12 h (ACHN) or 24 h (769-P). Representative
images are shown (magnification: 100×).
Additional file 2: Figure S2. DcR3 expression does not affect
proliferation or clonogenicity in RCC. (A) Proliferation assay of ACHN
and 769-P cells 24, 48 and 72 h after transfection with two different
DcR3-specific siRNAs or a non-specific siRNA (scram). Cells were
trypsinized and counted (mean ± SEM; n=3). (B) Proliferation assay of
ACHN and 769-P cells stably overexpressing DcR3 or an empty vector
control (neo) after 24, 48 and 72 h. Cells were trypsinized and counted
(mean ± SEM; n=3). (C) Clonogenicity assay of ACHN and 769-P cells
transfected with two different DcR3-specific siRNAs or a non-specific
siRNA (scram). Cells were grown for 7–9 days, subsequently stained withcrystal violet and colonies were counted (mean ± SEM; n=3).
(D) Clonogenicity assay of ACHN and 769-P cells stably overexpressing
DcR3 or an empty vector control (neo). Cells were grown for 7–9 days,
subsequently stained with crystal violet and colonies were counted
(mean ± SEM; n=3).
Additional file 3: Figure S3. NFAT mediated DcR3 expression is
PI3K/AKT dependent. (A) Relative Forkhead response element–luciferase
reporter activity of ACHN and 769-P cells 24 h after treatment with
LY294002 (50 μM) or AKT-inhibitor IV (10 μM) (mean ± SEM; n=3; *p<0.05;
T-test). (B) Relative Forkhead response element–luciferase reporter activity
of ACHN and 769-P cells 24 h post transfection with myrAKT or an empty
vector control (neo) (mean ± SEM; n=3; **p<0.01, ***p<0.001; T-test).
(C) Representative immunoblot analysis of whole-cell lysates of ex vivo
tissue 48 h after treatment with LY294002 (100 μM).
Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
DW carried out the experiments, participated in study conception and
design, analyzed and interpreted the data, and was involved in drafting the
manuscript. KET participated in study conception and design, analyzed and
interpreted the data, and was involved in drafting the manuscript. SMG
participated in study conception and design, and revised the manuscript for
important intellectual content. AH participated in study conception and
design, and revised the manuscript for important intellectual content. NW
participated in study conception and design, and revised the manuscript for
important intellectual content. WR participated in study conception and
design, analyzed and interpreted the data, and was involved in drafting the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank all laboratory members for helpful suggestions and
discussions. We further thank Prof. Dr. Volker Ellenrieder (Department of
Gastroenterology, Endocrinology and Metabolism, University Hospital
Giessen and Marburg) for providing plasmids and antibodies. Moreover we
thank Lena Pawella, Michaela Bissinger and Kai Breuhahn (Institute of
Pathology, University of Heidelberg) for introduction in the Olympus
Imaging System and the Mixer Mill MM 200. We also thank Sarah Messnard
and Vanessa Vogel (Institute of Pathology, University of Heidelberg) for
technical support. Furthermore we would like to thank Andrea Hain and the
NCT for technical support and tissue supply. In addition we thank Anjana
Rao, Michael Greenberg, Richard Roth and Jerry Crabtree for providing
plasmids via Addgene. This study was supported by funds from German
Cancer Aid (Deutsche Deutsche Krebshilfe; #109690; NW and WR); and
Heinrich F.C. Behr Foundation (stipend to DW).
Author details
1Molecular Tumor-Pathology, German Cancer Research Center (DKFZ),
Heidelberg 69120, Germany. 2Institute of Pathology, University of Heidelberg,
Heidelberg 69120, Germany. 3Department of Urology, University of Frankfurt
am Main, Frankfurt am Main 60590, Germany. 4Department of Urology,
Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
5Department of Urology, University of Heidelberg, Heidelberg 69120,
Germany.
Received: 8 July 2013 Accepted: 4 October 2013
Published: 10 October 2013
References
1. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005,
353:2477–2490.
2. Schmidinger M, Bellmunt J: Plethora of agents, plethora of targets,
plethora of side effects in metastatic renal cell carcinoma. Cancer Treat
Rev 2010, 36:416–424.
3. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000,
163:408–417.
4. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative
regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Proc Natl Acad Sci U S A 1996, 93:10595–10599.
Weissinger et al. Molecular Cancer 2013, 12:120 Page 14 of 15
http://www.molecular-cancer.com/content/12/1/1205. Tostain J, Li G, Gentil-Perret A, Gigante M: Carbonic anhydrase 9 in clear
cell renal cell carcinoma: a marker for diagnosis, prognosis and
treatment. Eur J Cancer 2010, 46:3141–3148.
6. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear
cell renal carcinoma. Clin Cancer Res 2007, 13:680s–684s.
7. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB: The role of mammalian
target of rapamycin inhibitors in the treatment of advanced renal
cancer. Clin Cancer Res 2007, 13:758s–763s.
8. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A,
Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL,
Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A: Genomic
amplification of a decoy receptor for Fas ligand in lung and colon
cancer. Nature 1998, 396:699–703.
9. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M,
Ohgaki H, Ashkenazi A, Weller M: Soluble decoy receptor 3 is expressed
by malignant gliomas and suppresses CD95 ligand-induced apoptosis
and chemotaxis. Cancer Res 2001, 61:2759–2765.
10. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW: Soluble decoy
receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine
belonging to tumor necrosis factor superfamily and exhibiting
angiostatic action. Cancer Res 2004, 64:1122–1129.
11. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW,
Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS,
Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM,
Wei P: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as
a T cell costimulator. Immunity 2002, 16:479–492.
12. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS: A newly identified member
of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-
mediated apoptosis. J Biol Chem 1999, 274:13733–13736.
13. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J: Mouse T cells receive
costimulatory signals from LIGHT, a TNF family member. Blood 2002,
100:3279–3286.
14. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL:
Modulation of macrophage differentiation and activation by decoy
receptor 3. J Leukoc Biol 2004, 75:486–494.
15. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW: Decoy receptor 3
(DcR3) induces osteoclast formation from monocyte/macrophage
lineage precursor cells. Cell Death Differ 2004, 11(Suppl 1):S97–S107.
16. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A,
Galloway SM, Liu Q, Austin CP, Caskey CT: Overexpression of M68/DcR3 in
human gastrointestinal tract tumors independent of gene amplification and
its location in a four-gene cluster. Proc Natl Acad Sci U S A 2000, 97:1230–1235.
17. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi
H, Koizumi M, Toyoda E, Ito D, Kami K, Mori T, Fujimoto K, Doi R, Imamura
M: Endogenous decoy receptor 3 blocks the growth inhibition signals
mediated by Fas ligand in human pancreatic adenocarcinoma. Int J
Cancer 2003, 106:17–25.
18. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J: Clinical
significance of detecting elevated serum DcR3/TR6/M68 in malignant
tumor patients. Int J Cancer 2003, 105:724–732.
19. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE,
Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W:
Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia
2008, 10:1049–1056.
20. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen
CC, Gau JP, Yang MH: Expression of a soluble decoy receptor 3 in
patients with diffuse large B-cell lymphoma predicts clinical outcome. Int
J Oncol 2008, 33:549–554.
21. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida
H, Hirao S, Mizuno T, Nakajima Y: The prognostic significance of
overexpression of the decoy receptor for Fas ligand (DcR3) in patients
with gastric carcinomas. Gastric Cancer 2002, 5:61–68.
22. Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen I: Tenascin and
fibronectin isoforms in human renal cell carcinomas, renal cell
carcinoma cell lines and xenografts in nude mice. Int J Cancer 1995,
63:442–449.
23. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,
MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL,
Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D:
VEGFR1-positive haematopoietic bone marrow progenitors initiate the
pre-metastatic niche. Nature 2005, 438:820–827.24. Porta C, Figlin RA: Phosphatidylinositol-3-kinase/Akt signaling pathway
and kidney cancer, and the therapeutic potential of
phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 2009, 182:2569–2577.
25. Macian F: NFAT proteins: key regulators of T-cell development and
function. Nat Rev Immunol 2005, 5:472–484.
26. Ho CH, Chen CL, Li WY, Chen CJ: Decoy receptor 3, upregulated by
Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal
carcinoma cell migration and invasion. Carcinogenesis 2009, 30:1443–1451.
27. Ge Z, Sanders AJ, Ye L, Wang Y, Jiang WG: Expression of death decoy
receptor-3 (DcR3) in human breast cancer and its functional effects on
breast cancer cells in vitro. J Exp Ther Oncol 2011, 9:109–118.
28. Connor JP, Felder M, Kapur A, Onujiogu N: DcR3 binds to ovarian cancer
via heparan sulfate proteoglycans and modulates tumor cells response
to platinum with corresponding alteration in the expression of BRCA1.
BMC Cancer 2012, 12:176.
29. Tateishi K, Miura Y, Hayashi S, Takahashi M, Kurosaka M: DcR3 protects
THP-1 macrophages from apoptosis by increasing integrin alpha4.
Biochem Biophys Res Commun 2009, 389:593–598.
30. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA: Cadherins and
integrins in renal cell carcinoma: an immunohistochemical study.
Tumori 2001, 87:173–178.
31. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M: CXCR4 chemokine
receptor and integrin signaling co-operate in mediating adhesion and
chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005,
24:4462–4471.
32. Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR:
Constitutive expression of the alpha4 integrin correlates with tumorigenicity
and lymph node metastasis of the B16 murine melanoma. Neoplasia 2010,
12:173–182.
33. Yang CR, Hsieh SL, Ho FM, Lin WW: Decoy receptor 3 increases monocyte
adhesion to endothelial cells via NF-kappa B-dependent up-regulation of
intercellular adhesion molecule-1, VCAM-1, and IL-8 expression.
J Immunol 2005, 174:1647–1656.
34. Song K, Zhu F, Zhang HZ, Shang ZJ: Tumor necrosis factor-alpha enhanced
fusions between oral squamous cell carcinoma cells and endothelial cells
via VCAM-1/VLA-4 pathway. Exp Cell Res 2012, 318:1707–1715.
35. Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H: Expression
of matrix metalloproteinase-7 on cancer cells and tissue endothelial
cells in renal cell carcinoma: prognostic implications and clinical
significance for invasion and metastasis. Clin Cancer Res 2006,
12:6998–7003.
36. Paule B, Deslandes E, Le Mouel SP, Bastien L, Podgorniak MP, Allory Y, de la
Taille A, Menashi S, Calvo F, Mourah S: Identification of a novel biomarker
signature associated with risk for bone metastasis in patients with renal
cell carcinoma. Int J Biol Markers 2010, 25:112–115.
37. Chang YC, Chan YH, Jackson DG, Hsieh SL: The glycosaminoglycan-
binding domain of decoy receptor 3 is essential for induction of
monocyte adhesion. J Immunol 2006, 176:173–180.
38. Bourguignon LY, Zhu H, Shao L, Chen YW: CD44 interaction with c-Src
kinase promotes cortactin-mediated cytoskeleton function and
hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem
2001, 276:7327–7336.
39. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC:
Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2)
and induces Rac1 and Ras signaling during ovarian tumor cell migration
and growth. J Biol Chem 2001, 276:48679–48692.
40. De Oliveira T, Abiatari I, Raulefs S, Sauliunaite D, Erkan M, Kong B, Friess H,
Michalski CW, Kleeff J: Syndecan-2 promotes perineural invasion and
cooperates with K-ras to induce an invasive pancreatic cancer cell
phenotype. Mol Cancer 2012, 11:19.
41. Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, Chio CC, Hsieh SL:
Enhanced adhesion of monocytes via reverse signaling triggered by
decoy receptor 3. Exp Cell Res 2004, 292:241–251.
42. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE: Therapeutic
targeting of STAT3 (signal transducers and activators of transcription 3)
pathway inhibits experimental autoimmune uveitis. PLoS One 2012,
7:e29742.
43. Fukuda A, Wang SC, Morris JP, Folias AE, Liou A, Kim GE, Akira S, Boucher
KM, Firpo MA, Mulvihill SJ, Hebrok M: Stat3 and MMP7 contribute to
pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell
2011, 19:441–455.
Weissinger et al. Molecular Cancer 2013, 12:120 Page 15 of 15
http://www.molecular-cancer.com/content/12/1/12044. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human
pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-,
Akt-, and NF-kappa B-dependent pathway. J Immunol 2008,
181:8441–8449.
45. Ho CH, Hsu CF, Fong PF, Tai SK, Hsieh SL, Chen CJ: Epstein-Barr virus
transcription activator Rta upregulates decoy receptor 3 expression by
binding to its promoter. J Virol 2007, 81:4837–4847.
46. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A, Cheng J, Lu G, Morris DJ,
Castrillon DH, Gerard RD, Rothermel BA, Hill JA: Foxo transcription factors
blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation
2006, 114:1159–1168.
47. Cai T, Li X, Ding J, Luo W, Li J, Huang C: A cross-talk between NFAT and
NF-kappaB pathways is crucial for nickel-induced COX-2 expression in
Beas-2B cells. Curr Cancer Drug Targets 2011, 11:548–559.
48. Liu Q, Chen Y, Auger-Messier M, Molkentin JD: Interaction between
NFkappaB and NFAT coordinates cardiac hypertrophy and pathological
remodeling. Circ Res 2012, 110:1077–1086.
49. Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-kappaB signaling
pathways. Nat Immunol 2011, 12:695–708.
50. Lawrence MC, Naziruddin B, Levy MF, Jackson A, McGlynn K: Calcineurin/
nuclear factor of activated T cells and MAPK signaling induce TNF-
{alpha} gene expression in pancreatic islet endocrine cells. J Biol Chem
2011, 286:1025–1036.
51. Lee HL, Bae OY, Baek KH, Kwon A, Hwang HR, Qadir AS, Park HJ, Woo KM,
Ryoo HM, Baek JH: High extracellular calcium-induced NFATc3 regulates
the expression of receptor activator of NF-kappaB ligand in osteoblasts.
Bone 2011, 49:242–249.
52. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher LH,
Fenton MJ, Gordon DC, Dunn IF, Goldfeld AE: A lipopolysaccharide-specific
enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein
and p300 is recruited to the tumor necrosis factor alpha promoter
in vivo. Mol Cell Biol 2000, 20:6084–6094.
53. Wang Q, Ji Y, Wang X, Evers BM: Isolation and molecular characterization
of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res
Commun 2000, 276:466–471.
54. Xiao S, Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Widom RL, Ju ST: FasL
promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and
Egr-3. Eur J Immunol 1999, 29:3456–3465.
55. Yoshida T, Sakai T: Promoter of TRAIL-R2 gene. Vitam Horm 2004, 67:35–49.
56. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB,
Kundra V, Shu HK, Peng Q, Durden DL: A vascular targeted pan
phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor
and antiangiogenic activity. Cancer Res 2008, 68:206–215.
57. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi
W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker
MD, Garlich JR, Durden DL, Ramanathan RK: Phase I pharmacokinetic and
pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-
drug SF1126 in patients with advanced solid tumours and B-cell
malignancies. Eur J Cancer 2012, 48:3319–3327.
58. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF,
Waterfield MD: Exploring the specificity of the PI3K family inhibitor
LY294002. Biochem J 2007, 404:15–21.
59. Engelman JA: Targeting PI3K signalling in cancer: opportunities,
challenges and limitations. Nat Rev Cancer 2009, 9:550–562.
60. Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl
A, Kuczyk MA: Activation of PI3K is associated with reduced survival in
renal cell carcinoma. Urol Int 2008, 80:372–377.
61. Schmitt M, Pawlita M: High-throughput detection and multiplex
identification of cell contaminations. Nucleic Acids Res 2009, 37:e119.
62. Kohn AD, Takeuchi F, Roth RA: Akt, a pleckstrin homology domain
containing kinase, is activated primarily by phosphorylation. J Biol Chem
1996, 271:21920–21926.
63. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon
A, Crabtree GR: NF-AT components define a family of transcription
factors targeted in T-cell activation. Nature 1994, 369:497–502.
64. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ,
Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by
phosphorylating and inhibiting a Forkhead transcription factor.
Cell 1999, 96:857–868.
65. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling
enzyme in T-lymphocyte activation. Nature 1992, 357:695–697.66. Fassl A, Tagscherer KE, Richter J, Berriel Diaz M, Alcantara Llaguno SR,
Campos B, Kopitz J, Herold-Mende C, Herzig S, Schmidt MH, Parada LF,
Wiestler OD, Roth W: Notch1 signaling promotes survival of glioblastoma
cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene
2012, 31:4698–4708.
67. Wessel D, Flugge UI: A method for the quantitative recovery of protein in
dilute solution in the presence of detergents and lipids. Anal Biochem
1984, 138:141–143.
68. Gillies RJ, Didier N, Denton M: Determination of cell number in monolayer
cultures. Anal Biochem 1986, 159:109–113.
doi:10.1186/1476-4598-12-120
Cite this article as: Weissinger et al.: The soluble Decoy Receptor 3 is
regulated by a PI3K-dependent mechanism and promotes migration
and invasion in renal cell carcinoma. Molecular Cancer 2013 12:120.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
